ERBB2 and neoplasm: It was seen that HER2 negative and HER2 low patients have similar prognosis regardless of hormone receptor status [9, 12] but it was noted that HR-positive tumours with HER2 low status have better disease-free survival (DFS) rates than HR-positive/ HER2 negative [9].